US Patent No: 8,304,383

Number of patents in Portfolio can not be more than 2000

Dissolution of arterial plaque

ALSO PUBLISHED AS: 20080187569

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Embodiments of methods of treating atherosclerosis are described. In some embodiments an emulsifier is provided to achieve levels in the systemic circulation that are effective to solubilize atherosclerotic plaque, resulting in plaque regression. In some embodiments, levels of greater than 50 μM are achieved; in some embodiments levels ranging from about 100 μM to about 600 μM are achieved; in some embodiments, levels ranging from about 100 μM to about 300 μM are achieved. Emulsifiers can include bile salts, saponins, and ionic, nonionic, and zwitterionic detergents, or salts, conjugates, hydrates, solvates, or polymorphs thereof. In some embodiments, a statin can be administered simultaneously or sequentially with an emulsifier.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ATHERONOVA OPERATIONS, INC.LAGUNA NIGUEL, CA2

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Zadini, Filiberto 16814 Rayen St., North Hills, CA 91343 21 163
Zadini, Giorgio 2237 Hilltop La., Camarillo, CA 93012 28 199

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Z & Z MEDICAL HOLDINGS, INC. (5)
2006/0222,695 Deoxycholic acid liposome-based dermatological topical preparation 10 2005
2007/0116,754 Dissolution of arterial cholesterol plaques by pharmacological preparation 2 2006
2007/0116,755 Dissolution of arterial cholesterol plaques by pharmacological preparation 2 2006
2007/0249,543 Dissolution of arterial cholesterol plaques by phytochemical emulsifiers 2 2006
2007/0129,425 Dissolution of arterial cholesterol plaques by pharmacological preparation 2 2007
 
Angiotech International AG (2)
2005/0177,225 Medical implants and anti-scarring agents 19 2004
2005/0249,770 Compositions and methods for treating or preventing inflammatory diseases 11 2005
 
ATHERONOVA OPERATIONS, INC. (1)
2008/0187,569 DISSOLUTION OF ARTERIAL PLAQUE 2 2008
 
BOSTON SCIENTIFIC SCIMED, INC. (1)
6,780,849 Lipid-based nitric oxide donors 25 2000
 
CHILDREN'S HOSPITAL RESEARCH FOUNDATION (1)
6,849,257 Lipid hydrolysis therapy for atherosclerosis and related diseases 3 2001
 
CIFTCIOGLU, NEVA (1)
6,706,290 Methods for eradication of nanobacteria 16 1999
 
CORDIS CORPORATION (1)
2008/0181,927 DEVICE FOR LOCAL AND/OR REGIONAL DELIVERY EMPLOYING LIQUID FORMULATIONS OF THERAPEUTIC AGENTS 6 2008
 
CORIUM INTERNATIONAL, INC. (1)
2003/0027,833 Compositions and delivery systems for administration of a local anesthetic agent 18 2002
 
DSM NUTRITIONAL PRODUCTS, INC. (1)
5,902,738 Enzymatic acylation 7 1997
 
GP MEDICAL, INC. (1)
2005/0163,821 Drug-eluting Biodegradable Stent and Delivery Means 49 2005
 
IDEA AG (1)
6,165,500 Preparation for the application of agents in mini-droplets 35 1992
 
INNOVATIONAL HOLDINGS LLC (1)
2004/0143,322 Method and apparatus for treating vulnerable artherosclerotic plaque 47 2003
 
KENSEY NASH CORPORATION (1)
2004/0267,354 Method for making a porous polymeric material 11 2004
 
MEDICAL RESEARCH FOUNDATION OF OREGON, A NON-PROFIT CORP. OF OR. (1)
4,602,003 Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia 54 1982
 
MEDTRONIC VASCULAR, INC. (1)
2005/0070,997 Laminated drug-polymer coated stent with dipped and cured layers 19 2003
 
MILLENNIUM PHARMACEUTICALS, INC. (1)
2007/0037,203 Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor 10 2006
 
NAT CITY BANK OF MIDWEST (1)
2004/0151,716 Material and method for treating microbial mediated dermatological conditions 5 2004
 
Noven Pharmaceuticals, Inc. (1)
5,446,070 Compositions and methods for topical administration of pharmaceutically active agents 194 1993
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1)
2005/0261,258 Methods and compositions for the non-surgical removal of fat 16 2005
 
THE UNIVERSITY OF BRITISH COLUMBIA (1)
5,837,282 Ionophore-mediated liposome loading 26 1996
 
UNIVERSITY OF CHICAGO, THE (1)
2006/0111,299 Compositions and methods for treating atherosclerosis 3 2005
 
UNIVERSITY OF SASKATCHEWAN (1)
5,597,807 Quinoa saponin compositions and methods of use 6 1994
 
VASCULAR DESIGNS, INC. (1)
2005/0267,407 Multi-function catheter and use thereof 9 2005
 
Other [Check patent profile for assignment information] (2)
6,423,742 Compositions for reducing vascular plaque formation and methods of using same 10 2000
2005/0158,408 Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof 13 2004

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 May 6, 2016
7.5 Year Payment $3600.00 $1800.00 $900.00 May 6, 2020
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 6, 2024
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00